2026-04-29T13:44:23Z https://www.peertechzpublications.org/oai-pmh

oai:www.peertechzpublications.org:10.17352/raoa.000007 2017-11-20 PTZ.RAOA:VOL1

Remission of Glucocorticoid-Resistant Polymyalgia Rheumatica achieved with Tocilizumab: 2 Case Reports Ayse Unal Enginar<p>Polymyalgia rheumatica (PMR) is an idiopathic inflammatory disease characterized by pain and stiffness around the shoulders, neck and hips. IL-6 is an important cytokine in the pathogenesis of the disease. Although glucocorticoids (GC) are the current basic treatment, approximately 50% of patients may experience relapses during treatment. There have been case reports of resistant patients treated with Tocilizumab (TCZ), but as there has been insuffi cient evidence, the 2015 EULAR-ACR did not include TCZ treatment in the PMR recommendations.Two cases of GC-resistant PMR cases where remission was obtained with TCZ treatment are presented in this paper.</p> Rheumatica Acta: Open Access - Peertechz Publications 2017-11-20 Case Report https://doi.org/10.17352/raoa.000007 en Copyright © Ayse Unal Enginar et al.